Site Editors

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Advertisement
Advertisement

NTRK Gene Fusion Linked to Case of Infantile Fibrosarcoma

By: Vanessa A. Carter, BS
Posted: Friday, July 22, 2022

Hedwig E. Deubzer, MD, of Charité—Universitätsmedizin Berlin, and colleagues presented a case of ETV6-NTRK3–driven infantile fibrosarcoma that developed resistance to first- and second-generation TRK inhibitors. According to the investigators, an increase in the dose of the second-generation TRK inhibitor selitrectinib combined with the MEK1/2 inhibitor trametinib offered a significant treatment benefit, without detectable evidence of organ toxicity. This case report was published in JCO Precision Oncology.

A 13-month-old patient presented with progressing respiratory insufficiency that required invasive mechanical ventilation. A large right-sided intrathoracic mass was identified, but histopathologic analysis remained inconclusive. After two cycles of adjuvant chemotherapy, a third biopsy confirmed ETV6-NTRK3 fusion–positive infantile fibrosarcoma. The patient was then enrolled in a phase I/II trial for the first-generation TRK inhibitor larotrectinib but experienced disease progression after 4 months of treatment; the tumor continued to grow with subsequent chemotherapy.

Single-nucleotide variant analysis detected a mutation in NTRK3 that rendered larotrectinib ineffective, and therefore the patient was enrolled in a phase I/II trial of selitrectinib. A partial response was achieved after 2.5 months on treatment, but disease progression continued after 3 months. Selitrectinib was administered again after a gross tumor resection with bilobectomy was performed, but there was notable disease progression 6 weeks after surgery.

Due to the resistance to monotherapy with TRK inhibitors, the study authors increased the total dose of selitrectinib to 87 mg/m2 twice daily and combined it with trametinib. The reason for the addition of this agent was because oncogenic NTRK fusions may mediate elevated RAS/MAPK/ERK signaling cascade activity. After being administered this combination treatment, the patient did not experience disease progression for more than 1 year.

Disclosure: For full disclosures of the study authors, visit ascopubs.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.